Know the news early: Efficacy and side effects of tremelimumab/tremelimumab

Tremelimumab/tremelimumab is an immunotherapy drug that enhances the immune system’s killing effect on tumor cells by inhibiting the interaction between tumor cells and immune cells. Its mechanism of action is to inhibit the CTLA-4 signaling pathway, enhance the activation and proliferation of T cells, and promote tumor immune response. Therefore, the efficacy of tremelimumab/tematumumab includes treating tumors, inhibiting tumor growth and spread, etc.

Tremelimumab is a cytotoxic drug that reduces tumor growth. In vitro, there is no evidence that tremelimumab or drug binding to Fc receptors induces nonspecific cytokine release. However, the use of tremelimumab may also cause some side effects, including nausea, anorexia, fatigue, neutropenia, leukopenia, lymphopenia, anemia, hyponatremia, elevated lipase, and thrombocytopenia. In addition, some side effects may occur during treatment but usually disappear after stopping the drug, such as fever, muscle pain, rash, mouth ulcers, and hypothyroidism.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.